Tuesday, April 21, 2015 8:08:22 PM
Wound Management Technologies, Inc. Schedules First Quarter 2015 Earnings Call for Wednesday, April 22, 2015
share with linkedin tweet share with facebook
ADDISON, TX / ACCESSWIRE / April 20, 2015 / Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced it will conduct a quarterly earnings call on Wednesday, April 22, 2015 at 3:00 p.m. CST. Robert Lutz, Jr., CEO, will discuss first quarter 2015 results and provide and update on recent activities. A question and answer session will follow the presentation. Shareholders, analysts and other interested parties may join the call by dialing 1-712-775-7031 passcode 604070847# shortly before 3:00 p.m. CST.
About Wound Management Technologies
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its Wound Care Innovations subsidiary's unique, patented collagen product line, CellerateRX(R) which is FDA-cleared for all wound types except 3rd degree burns. The wound care product line is reimbursable under Medicare Part B and the surgical products are reimbursable as part of procedural billing. Wound Management has other advanced biotech products in development including a patented resorbable bone hemostat line that is in late stages of development. For more information visit http://www.wmgtech.com/.
To download Wound Management Technologies' investor relations app, which offers access to SEC documents, press releases, audio casts and more, please visit http://bit.ly/1zhNwnO to download on your iPhone and iPad or http://bit.ly/149PgWc for your Android mobile device.
Information about Forward-Looking Statements
The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the Company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
Investor Contacts:
Robert Lutz Jr. / Darren Stine
972.218.0935
rlutz@wmgtech.com / dstine@wmgtech.com
SOURCE: Wound Managemen
Recent SMTI News
- Sanara MedTech Inc. Announces $55 Million Debt Facility • GlobeNewswire Inc. • 04/18/2024 01:15:00 PM
- Sanara MedTech Inc. Announces the Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer • GlobeNewswire Inc. • 04/05/2024 01:00:00 PM
- Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results • GlobeNewswire Inc. • 03/25/2024 08:05:00 PM
- Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call Dates • GlobeNewswire Inc. • 03/13/2024 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:05:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:05:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:20:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:18:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:01:46 PM
- Sanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2023 • GlobeNewswire Inc. • 02/22/2024 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:29:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:27:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:05:58 PM
- Sanara MedTech Inc. Announces Exclusive License Agreement for Patented Collagen Peptides • GlobeNewswire Inc. • 01/03/2024 02:15:00 PM
- Sanara MedTech Inc. Announces the Publication of a 5,335 Patient Study Demonstrating a Significant Reduction in Surgical Site Infections When Activated Collagen (CellerateRX® Surgical Powder) Was Used to Promote Wound Healing • GlobeNewswire Inc. • 11/30/2023 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:42:17 PM
- Sanara MedTech Inc. Announces Third Quarter 2023 Results • GlobeNewswire Inc. • 11/13/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:02:43 PM
- Sanara MedTech Inc. Announces Third Quarter Earnings Release and Conference Call Dates • GlobeNewswire Inc. • 10/30/2023 01:15:00 PM
- Sanara MedTech Announces First Sale of ALLOCYTE® Plus Advanced Viable Bone Matrix and Provides Other Product Updates • GlobeNewswire Inc. • 10/10/2023 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/22/2023 08:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2023 12:00:44 PM
- Sanara MedTech to Participate in Two Upcoming Conferences • GlobeNewswire Inc. • 09/12/2023 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2023 10:02:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 09:11:16 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM